Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data

Lakewood-Amedex published a July 22, 2026 release highlighting new resistance data for Nu-3, its Phase 2-ready infected diabetic foot ulcer candidate. * Nu-3 showed no induced resistance in a serial-passage study, supporting its membrane-disruption mechanism and positioning in antimicrobial-resistance-focused development. * Release: here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY09340) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Lakewood-Amedex Biotherapeutics released data on July 22, 2026, regarding its Phase 2-ready candidate Nu-3 for infected diabetic foot ulcers. The new resistance data indicates no induced resistance in serial-passage studies, supporting the drug's membrane-disruption mechanism and its potential in antimicrobial-resistance-focused development.

Lakewood-Amedex published a July 22, 2026 release highlighting new resistance data for Nu-3, its Phase 2-ready infected diabetic foot ulcer candidate. * Nu-3 showed no induced resistance in a serial-passage study, supporting its membrane-disruption mechanism and positioning in antimicrobial-resistance-focused development. * Release: here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY09340) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)